Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer

Sudoł, Damian; Widz, Damian; Mitura, Przemysław; Płaza, Paweł; Godzisz, Michał; Kuliniec, Iga; Yadlos, Andriy; Cabanek, Michał; Bar, Marek; Bar, Krzysztof

doi:10.5173/ceju.2022.0273

Cited by 6 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, leukocytes, neutrophils and lymphocytes counts did not show significant differences between R and NR (Table 1), suggesting similar immune cell profiles among MIBC patients. Additionally, the ratio between neutrophils and lymphocytes , previously reported as an indicator of good NAC response 24 , was not significantly different between groups (Table 1). Both analyses followed a first quality control (QC) and were subsequently subjected to a preprocessing step.…”

Section: Patient Characteristics and Genomic Analysismentioning

confidence: 58%

Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers

Acedo-Terrades,

Rodriguez-Vida,

Buisan

et al. 2024

Preprint

View full text Add to dashboard Cite

Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit of NAC remains unclear for many patients due to the lack of reliable biomarkers predicting treatment response. In order to identify biomarkers and build an integrated and highly accurate model to predict NAC response, we performed a comprehensive transcriptomic and genomic profiling on tumors from 100 MIBC patients. Our results showed that the expression of the top genes associated with response, as well as the expression of growth factor genes and cell cycle regulators are highly correlated with NAC response. Most importantly, we found a novel signature related to the WNT signaling pathway that alone was highly correlated with NAC response and showed high accuracy in predicting NAC response (AUC=0.76). Additionally, mutations in the DNAH family genes (DNAH8, DNAH6 and DNAH10) and deletion in KDM6A were also highly correlated with NAC response. Using our comprehensive molecular analysis as a backbone, we developed two machine learning (ML) models, one incorporating both transcriptomic and genomic features (RF-RW), and the other using only transcriptomic data (RF-R). Both models demonstrated promising performance (AUC=0.82) as predictive models of response to NAC in MIBC. RF-RW and RF-R, after external validation, could potentially change the management of MIBC patients by selecting ideal candidates for NAC.

show abstract

Section: Patient Characteristics and Genomic Analysismentioning

confidence: 58%

Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers

Acedo-Terrades,

Rodriguez-Vida,

Buisan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In recent studies, the link between NLR and BC prognosis has been widely studied in pretreatment settings. Notably, the NLR obtained before a transurethral resection of bladder tumour (TURBT) was reported to predict disease recurrence, as well as survival outcomes in patients who underwent upfront RC [14,15]. These results were confirmed in a meta-analysis by Lucca et al [12], in which advanced tumour stage and lymph node metastasis have been associated with worse prognosis in patients with a high preoperative NLR.…”

Section: Introductionmentioning

confidence: 92%

Prognostic Value of Postneoadjuvant Chemotherapy Neutrophil-to-Lymphocyte Ratio in Patients undergoing Radical Cystectomy

Kaczmarek,

Małkiewicz,

Gurwin

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Neutrophil-to-lymphocyte ratio (NLR), a widely assessed biomarker in most common diseases, is typically evaluated before treatment initiation. However, data on NLR in the post-treatment setting is limited. Therefore, we assessed the NLR calculated after neoadjuvant chemotherapy (NAC) initiation in patients with bladder cancer (BC). We hypothesised that changes in blood cells after NAC could be a marker of tumour response and long-term survival. Materials and Methods: Our study included 214 patients who underwent NAC followed by radical cystectomy (RC) in two urological departments, wherein post-NAC NLR was used to categorize patients into the low (NLR ≤ 1.75) and high (NLR > 1.75) groups. Results: Logistic regression analysis indicated that a post-NAC NLR ≥ 1.75 is a good biomarker for pathologic response (odds ratio (OR), 0.045; p <0.001), emphasizing its ability to predict patient survival. The HRs for overall survival and cancer-specific survival were 2.387 (p = 0.048) and 2.342 (p < 0.001), respectively. Conclusions: We believe that post-NAC NLR can be used for patient stratification after NAC. Consequently, the post-NAC NLR may serve as a guide for the decision-making process regarding RC versus bladder-preserving strategies.

show abstract

“…Stage 4 bladder cancer has a 5-year survival rate of 15%, while stages 0 and 1 have survival rates of 98% and 88%, respectively (5). The classical prognostic indicators of bladder cancer include clinicopathological characteristics and Neutrophil-to-lymphocyte ratio (NLR) (6)(7)(8)(9)(10)(11)(12)(13), etc., which cannot meet the clinical needs of precision medicine. By stratifying patients' prognoses, it is important to continue to investigate novel prognostic markers and provide new indicators for tailored precise treatment.…”

Section: Introductionmentioning

confidence: 99%

Construction and prognostic value of enhanced CT image omics model for noninvasive prediction of HRG in bladder cancer based on logistic regression and support vector machine algorithm

Luo²,

Liu³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundUrothelial Carcinoma of the bladder (BLCA) is the most prevalent cancer of the urinary system. In cancer patients, HRG fusion is linked to a poor prognosis. The prediction of HRG expression by imaging omics in BLCA has not yet been fully investigated.MethodsHRG expression in BLCA and healthy adjoining tissues was primarily identified utilizing data sourced from The Cancer Genome Atlas (TCGA). Using Kaplan–Meier survival curves and Landmark analysis, the relationship between HRG expression, clinicopathological parameters, and overall survival (OS) was investigated. Additionally, gene set variation analysis (GSVA) was conducted and CIBERSORTx was used to investigate the relationship between HRG expression and immune cell infiltration. The Cancer Imaging Archive (TCIA) provided CT images that were used for prognostic analysis, radiomic feature extraction, and construction of the model, respectively. The HRG expression levels were predicted using the constructed and evaluated LR and SMV models.ResultsHRG expression was shown to be substantially lower in BLCA tumors as opposed to that observed in normal tissues (p < 0.05). HRG expression had a close positive relationship with Eosinophils and a close negative relationship with B cells naive. The findings of the Landmark analysis illustrated that higher HRG was associated with improved patient survival at an early stage (P=0.048). The predictive performance of the two models, based on logistic regression analysis and support vector machine, was outstanding in the training and validation sets, yielding AUCs of 0.722 and 0.708, respectively, in the SVM model, and 0.727 and 0.662, respectively, in the LR.The models have good predictive efficiency.ConclusionHRG expression levels can have a significant impact on BLCA patients’ prognoses. The radiomic characteristics can successfully predict the pre-surgical HRG expression levels, based on CT- Image omics.

show abstract

Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer

Cited by 6 publications

References 33 publications

Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers

Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers

Prognostic Value of Postneoadjuvant Chemotherapy Neutrophil-to-Lymphocyte Ratio in Patients undergoing Radical Cystectomy

Construction and prognostic value of enhanced CT image omics model for noninvasive prediction of HRG in bladder cancer based on logistic regression and support vector machine algorithm

Contact Info

Product

Resources

About